- 9. (Previously Presented) The method of claim 8, wherein the allergy is asthma.
- 10. (Previously Presented) The method of claim 5, whereby IgG-induced phagocytosis is inhibited.
- 11. (Previously Presented) The method of claim 10, whereby IgE-mediated exocytosis is further inhibited.
- 12. (Previously Presented) The method of claim 9, whereby antigen-induced bronchial hyper reactivity is prevented.
- 13. (Previously Presented) The method of claim 5, wherein the monovalent antibody fragments are administered in a form of a composition.
- 14. (Previously Presented) The method of claim 13, wherein the composition is administered by injection.
- 15. (Previously Presented) The method of claim 14, wherein the injection is intramuscular, intradermal, intravenous, intraperitoneal or subcutaneous.
- 16. (Previously Presented) The method of claim 13, wherein the composition is administered by aerosol.
- 17. (Previously Presented) The method of claim 5, wherein the mammal is human.
- 18. (Previously Presented) The method of claim 5, wherein the antibody fragments are Fab fragments of an anti-FcαRI mAb.
- 19. (Previously Presented) The method of claim 18, wherein the anti- FcaRI mAb is (IgGlk, clone A 77).
- 20. (Previously Presented) A pharmaceutical composition, comprising:
 - a) monovalent antibody fragments directed against mammalian

FcaRI receptor, and

b) a carrier.

- 21. (Previously Presented) The pharmaceutical composition of claim 20, in a form suitable for injection.
- 22. (Previously Presented) The pharmaceutical composition of claim 20, in a form suitable for inhalation.
- 23. (Previously Presented) The pharmaceutical composition of claim 20, wherein the monovalent antibody fragments are directed against EC2 domain of the FcαR1 receptor.
- 24. (Previously Presented) The pharmaceutical composition of claim 20, wherein the antibody fragments of an anti- FcαRI mAb.
- 25. (Previously Presented) The pharmaceutical composition of claim 24, wherein the anti-FcaRI mAb is (IgGlk, clone A 77).